You just read:

Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.

News provided by

Novo Nordisk Canada Inc.

Nov 21, 2017, 08:00 ET